Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02937077 : Atrial Fibrillation in Cryptogenic Stroke and TIA
AgesMin: 18 Years Max: 80 Years
Inclusion Criteria:

1. Cryptogenic ischemic stroke patients or symptomatic TIA < 21 days from symptom start.

2. A stroke/TIA is considered to be cryptogenic if no cause can be determined despite an
extensive workup according to the standard protocol of the participating center.
Before inclusion to the study, the following tests are required as standard tests to
establish the diagnosis of cryptogenic stroke or TIA:

1. Brain MRI or CT†

2. 12-lead ECG for AF detection

3. 24-h ECG monitoring for AF detection and premature atrial complex analysis (e.g.

4. TEE (transesophageal echocardiography) highly recommended or TTE (transthoracic

5. Colour Duplex ultrasound examination of the pre-cerebral arteries

6. CTA or MRA of head and neck to rule out other causes of stroke pathologies

3. Age 18 to 80 at onset of TIA/stroke

4. A participation consent form signed by the patient or a legally authorized

- TIA cases with acute non-lacunar infarct on Diffusion Weighted Imaging are
included as TIA events.

Exclusion Criteria:

1. Known etiology of TIA or stroke.

2. TIA without documented cerebral ischemia on Diffusion Weighed Imaging.

3. Untreated hyperthyroidism

4. Myocardial infarction less than 1 month prior to the stroke or TIA.

5. Coronary bypass grafting less than 1 month prior to the stroke or TIA.

6. Valvular heart disease requiring immediate surgical intervention.

7. History of atrial fibrillation or atrial flutter.

8. Patent Foramen Ovale (PFO) or PFO where there is or was an indication to start oral

9. Permanent indication for OAC treatment at enrollment.

10. Permanent contra-indication for OAC.

11. Life expectancy less than 1 year.

12. Pregnancy

13. An indication for an Implantable Pulse Generator (IPG), Implantable
Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT) or an
implantable hemodynamic monitoring system.

14. Patient otherwise not eligible for the study or adherent for follow-up (e.g.
non-resident) or has concurrent disease which may affect clinical outcome (e.g.
multiple sclerosis, cancer).
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557